

# Helena Jernström

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3497376/publications.pdf>

Version: 2024-02-01

62  
papers

1,951  
citations

361413

20  
h-index

254184

43  
g-index

63  
all docs

63  
docs citations

63  
times ranked

2863  
citing authors

#	ARTICLE	IF	CITATIONS
1	Statin use and patterns of breast cancer recurrence in the Malmö Diet and Cancer Study. <i>Breast</i> , 2022, 61, 123-128.	2.2	11
2	Impact of combining vitamin C with radiation therapy in human breast cancer: does it matter?. <i>Oncotarget</i> , 2022, 13, 439-453.	1.8	4
3	Interplay between Caveolin-1 and body and tumor size affects clinical outcomes in breast cancer. <i>Translational Oncology</i> , 2022, 22, 101464.	3.7	3
4	Prognostic impact of tumor-specific insulin-like growth factor binding protein 7 (IGFBP7) levels in breast cancer: a prospective cohort study. <i>Carcinogenesis</i> , 2021, 42, 1314-1325.	2.8	8
5	Pre- and Postoperative Circulating IGF-I, IGFBP-3, and IGFBP-7 Levels in Relation to Endocrine Treatment and Breast Cancer Recurrence: A Nested Case-Control Study. <i>Frontiers in Oncology</i> , 2021, 11, 626058.	2.8	6
6	The Prognostic Impact of Intratumoral Aryl Hydrocarbon Receptor in Primary Breast Cancer Depends on the Type of Endocrine Therapy: A Population-Based Cohort Study. <i>Frontiers in Oncology</i> , 2021, 11, 642768.	2.8	4
7	Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1. <i>Molecular Cancer Research</i> , 2020, 18, 644-656.	3.4	17
8	CYP27A1 expression is associated with risk of late lethal estrogen receptor-positive breast cancer in postmenopausal patients. <i>Breast Cancer Research</i> , 2020, 22, 123.	5.0	14
9	Patient Characteristics Influence Activated Signal Transducer and Activator of Transcription 3 (STAT3) Levels in Primary Breast Cancer—Impact on Prognosis. <i>Frontiers in Oncology</i> , 2020, 10, 1278.	2.8	2
10	Prognostic Impact of Menopausal Hormone Therapy in Breast Cancer Differs According to Tumor Characteristics and Treatment. <i>Frontiers in Oncology</i> , 2020, 10, 80.	2.8	7
11	Re-evaluation of HER2 status in 606 breast cancers—gene protein assay on tissue microarrays versus routine pathological assessment. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 317-320.	2.8	12
12	The impact of body size changes on recurrence risk depends on age and estrogen receptor status in primary breast cancer. <i>Cancer Causes and Control</i> , 2019, 30, 1157-1170.	1.8	7
13	Patients' and physicians' disagreement on patients' understanding of clinical cancer trial information: a pairwise pilot study of mirroring subjective assessments compared with objective measurements. <i>Trials</i> , 2019, 20, 301.	1.6	6
14	Current smoking is associated with a larger waist circumference and a more androgenic profile in young healthy women from high-risk breast cancer families. <i>Cancer Causes and Control</i> , 2018, 29, 243-251.	1.8	7
15	Stellate cells and mesenchymal stem cells in benign mammary stroma are associated with risk factors for breast cancer—an observational study. <i>BMC Cancer</i> , 2018, 18, 230.	2.6	4
16	Patients' reasoning regarding the decision to participate in clinical cancer trials: an interview study. <i>Trials</i> , 2018, 19, 528.	1.6	33
17	Interactions Between ABCB1 Genotype and Preoperative Statin Use Impact Clinical Outcomes Among Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2018, 8, 428.	2.8	8
18	Increasing preoperative body size in breast cancer patients between 2002 and 2016: implications for prognosis. <i>Cancer Causes and Control</i> , 2018, 29, 643-656.	1.8	17

#	ARTICLE	IF	CITATIONS
19	Coffee Is Associated With Lower Breast Tumor Insulin-Like Growth Factor Receptor 1 Levels in Normal-Weight Patients and Improved Prognosis Following Tamoxifen or Radiotherapy Treatment. <i>Frontiers in Endocrinology</i> , 2018, 9, 306.	3.5	7
20	Androgen receptor expression and breast cancer mortality in a population-based prospective cohort. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 645-657.	2.5	34
21	High Estrogen Receptor $\beta$ Expression Is Prognostic among Adjuvant Chemotherapy-Treated Patients—Results from a Population-Based Breast Cancer Cohort. <i>Clinical Cancer Research</i> , 2017, 23, 766-777.	7.0	23
22	The prognostic impact of COX-2 expression in breast cancer depends on oral contraceptive history, preoperative NSAID use, and tumor size. <i>International Journal of Cancer</i> , 2017, 140, 163-175.	5.1	19
23	Body Mass Index Influences the Prognostic Impact of Combined Nuclear Insulin Receptor and Estrogen Receptor Expression in Primary Breast Cancer. <i>Frontiers in Endocrinology</i> , 2017, 8, 332.	3.5	5
24	Combined and individual tumor-specific expression of insulin-like growth factor-I receptor, insulin receptor and phospho-insulin-like growth factor-I receptor/insulin receptor in primary breast cancer: Implications for prognosis in different treatment groups. <i>Oncotarget</i> , 2017, 8, 9093-9107.	1.8	13
25	The absence of aldehyde dehydrogenase 1 A1-positive cells in benign mammary stroma is associated with risk factors for breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2016, 8, 117.	1.8	1
26	Impacts of smoking on endocrine treatment response in a prospective breast cancer cohort. <i>British Journal of Cancer</i> , 2016, 115, 382-390.	6.4	33
27	CYP1A2 — a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients. <i>BMC Cancer</i> , 2016, 16, 256.	2.6	11
28	Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. <i>EMBO Molecular Medicine</i> , 2015, 7, 1034-1047.	6.9	380
29	History of oral contraceptive use in breast cancer patients: impact on prognosis and endocrine treatment response. <i>Breast Cancer Research and Treatment</i> , 2015, 149, 505-515.	2.5	10
30	Caffeine and Caffeic Acid Inhibit Growth and Modify Estrogen Receptor and Insulin-like Growth Factor I Receptor Levels in Human Breast Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 1877-1887.	7.0	108
31	Combined Androgen and Estrogen Receptor Status in Breast Cancer: Treatment Prediction and Prognosis in a Population-Based Prospective Cohort. <i>Clinical Cancer Research</i> , 2015, 21, 3640-3650.	7.0	64
32	Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients. <i>BMC Clinical Pathology</i> , 2015, 15, 8.	1.8	26
33	Impact of a paternal origin of germline BRCA1/2 mutations on the age at breast and ovarian cancer diagnosis in a Southern Swedish cohort. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 39-50.	2.8	6
34	No association found between CYP2D6 genotype and early breast cancer events in tamoxifen-treated patients. <i>Acta Oncologica</i> , 2014, 53, 195-200.	1.8	15
35	Impact of COX2 genotype, ER status and body constitution on risk of early events in different treatment groups of breast cancer patients. <i>International Journal of Cancer</i> , 2014, 135, 1898-1910.	5.1	18
36	IL6 genotype, tumour ER-status, and treatment predicted disease-free survival in a prospective breast cancer cohort. <i>BMC Cancer</i> , 2014, 14, 759.	2.6	19

#	ARTICLE	IF	CITATIONS
37	Age at first childbirth and oral contraceptive use are associated with risk of androgen receptor-negative breast cancer: the Malmö Diet and Cancer Cohort. <i>Cancer Causes and Control</i> , 2014, 25, 945-957.	1.8	17
38	Pre- and postoperative alcohol consumption in breast cancer patients: impact on early events. SpringerPlus, 2014, 3, 261.	1.2	21
39	Excessive milk production during breast-feeding prior to breast cancer diagnosis is associated with increased risk for early events. SpringerPlus, 2013, 2, 298.	1.2	5
40	Given breast cancer, is fat better than thin? Impact of the estrogen receptor beta gene polymorphisms. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 849-862.	2.5	12
41	Coffee prevents early events in tamoxifen-treated breast cancer patients and modulates hormone receptor status. <i>Cancer Causes and Control</i> , 2013, 24, 929-940.	1.8	33
42	Abstract A126: Oral contraceptives and late first childbirth increase the risk of androgen receptor-negative breast cancer: The Malmö Diet and Cancer cohort. , 2013, , .		0
43	Abstract A127: Parental influence on breast cancer penetrance in BRCA1/2 mutation carriers: Impact of oral contraceptive use before age 20 years. , 2013, , .		0
44	Clinical Profiles Predict Early Nonadherence to Adjuvant Endocrine Treatment in a Prospective Breast Cancer Cohort. <i>Cancer Prevention Research</i> , 2012, 5, 735-745.	1.5	28
45	Given breast cancer, does breast size matter? Data from a prospective breast cancer cohort. <i>Cancer Causes and Control</i> , 2012, 23, 1307-1316.	1.8	29
46	IGF1 htSNPs in relation to IGF-1 levels in young women from high-risk breast cancer families: implications for early-onset breast cancer. <i>Familial Cancer</i> , 2011, 10, 173-185.	1.9	15
47	IGFBP1 and IGFBP3 polymorphisms predict circulating IGFBP-3 levels among women from high-risk breast cancer families. <i>Breast Cancer Research and Treatment</i> , 2011, 127, 785-794.	2.5	12
48	Natural remedy use in a prospective cohort of breast cancer patients in southern Sweden. <i>Acta Oncologica</i> , 2011, 50, 134-143.	1.8	20
49	<i>IGF1</i> and <i>IGFBP3</i> Polymorphisms and Plasma Levels in Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2794-2794.	2.5	2
50	Prolactin levels, breast-feeding and milk production in a cohort of young healthy women from high-risk breast cancer families: implications for breast cancer risk. <i>Familial Cancer</i> , 2008, 7, 221-228.	1.9	11
51	Coffee Consumption and <i>CYP1A2*1F</i> Genotype Modify Age at Breast Cancer Diagnosis and Estrogen Receptor Status. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 895-901.	2.5	42
52	Absence of the common IGF1 19 CA-repeat allele is more common among BRCA1 mutation carriers than among non-carriers from BRCA1 families. <i>Familial Cancer</i> , 2007, 6, 445-452.	1.9	6
53	Comparison of plasma and urinary levels of 2-hydroxyestrogen and 16 $\alpha$ -hydroxyestrogen metabolites. <i>Molecular Genetics and Metabolism</i> , 2006, 87, 135-146.	1.1	18
54	Differences in IGFBP-3 regulation between young healthy women from BRCA1/2 families and those belonging to BRCA1/2 families. <i>European Journal of Cancer Prevention</i> , 2006, 15, 233-241.	1.3	7

#	ARTICLE	IF	CITATIONS
55	Of cup and bra size: Reply to a prospective study of breast size and premenopausal breast cancer incidence. <i>International Journal of Cancer</i> , 2006, 119, 2242-2243.	5.1	46
56	Impact of teenage oral contraceptive use in a population-based series of early-onset breast cancer cases who have undergone BRCA mutation testing. <i>European Journal of Cancer</i> , 2005, 41, 2312-2320.	2.8	57
57	High follicular phase luteinizing hormone levels in young healthy BRCA1 mutation carriers: Implications for breast and ovarian cancer risk. <i>Molecular Genetics and Metabolism</i> , 2005, 86, 320-327.	1.1	9
58	A prospective study of different types of hormone replacement therapy use and the risk of subsequent breast cancer: the women's health in the Lund area (WHILA) study (Sweden). <i>Cancer Causes and Control</i> , 2003, 14, 673-680.	1.8	52
59	Oral Contraceptives and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1773-1779.	6.3	318
60	Genetic Factors Related to Racial Variation in Plasma Levels of Insulin-Like Growth Factor-1: Implications for Premenopausal Breast Cancer Risk. <i>Molecular Genetics and Metabolism</i> , 2001, 72, 144-154.	1.1	101
61	Obesity, Weight Change, Fasting Insulin, Proinsulin, C-Peptide, and Insulin-like Growth Factor-1 Levels in Women with and without Breast Cancer: The Rancho Bernardo Study. <i>Journal of Women's Health and Gender-Based Medicine</i> , 1999, 8, 1265-1272.	1.5	97
62	Suppression of Plasma Insulin-Like Growth Factor-1 Levels in Healthy, Nulliparous, Young Women Using Low Dose Oral Contraceptives. <i>Gynecologic and Obstetric Investigation</i> , 1994, 38, 261-265.	1.6	22